Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction

Brian Godman; Ana Luísa Caires de Souza; Francisco de Assis Acurcio; Augusto Afonso Guerra Júnior

Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction

Brian Godman, Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to conference › Abstract › peer-review

63 Downloads (Pure)

Abstract

The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

Original language	English
Number of pages	1
Publication status	Published - 2014
Event	II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment” - Brazil, Belo Horizonte, United Kingdom Duration: 10 Nov 2014 → 13 Nov 2014

Conference

Conference	II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”
Country/Territory	United Kingdom
City	Belo Horizonte
Period	10/11/14 → 13/11/14

Keywords

insulin glargine
systematic review
Brazil
law suits

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Godman-etal-ISPSUS-2014-Insulin-glargine-in-a-Brazilian-State-an-assessment-of-drug-utilizationAccepted author manuscript, 157 KB

Cite this

Godman, Brian ; de Souza, Ana Luísa Caires ; de Assis Acurcio, Francisco ; Guerra Júnior, Augusto Afonso. / Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.1 p.

@conference{e7f4fb504b944d5197972447a4a31194,

title = "Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction",

abstract = "The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.",

keywords = "insulin glargine, systematic review, Brazil, law suits",

author = "Brian Godman and {de Souza}, {Ana Lu{\'i}sa Caires} and {de Assis Acurcio}, Francisco and {Guerra J{\'u}nior}, {Augusto Afonso}",

year = "2014",

language = "English",

note = "II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment” ; Conference date: 10-11-2014 Through 13-11-2014",

}

Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction. / Godman, Brian; de Souza, Ana Luísa Caires; de Assis Acurcio, Francisco; Guerra Júnior, Augusto Afonso.

2014. Abstract from II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”, Belo Horizonte, United Kingdom.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Insulin glargine in a Brazilian State

T2 - II International Symposium on Pharmacoeconomics in SUS – “Health Technologies Assessment”

AU - Godman, Brian

AU - de Souza, Ana Luísa Caires

AU - de Assis Acurcio, Francisco

AU - Guerra Júnior, Augusto Afonso

PY - 2014

Y1 - 2014

N2 - The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

AB - The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

KW - insulin glargine

KW - systematic review

KW - Brazil

KW - law suits

UR - http://www.farmacoeconomiasus.com.br/sobre_en.html

M3 - Abstract

Y2 - 10 November 2014 through 13 November 2014

ER -

Insulin glargine in a Brazilian State: an assessment of drug utilization, effectiveness and value to provide future direction

Abstract

Conference

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this